Verrica Pharmaceuticals (VRCA) Competitors

Verrica Pharmaceuticals (NASDAQ:VRCA) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

Which has higher earnings & valuation, VRCA or INBX?

Inhibrx Biosciences has lower revenue, but higher earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$7.57M	7.34	-$76.58M	-$1.20	-0.50
Inhibrx Biosciences	$200K	1,062.11	$1.69B	$116.75	0.13

Is VRCA or INBX more profitable?

Verrica Pharmaceuticals' return on equity of 0.00% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	N/A	N/A	-145.63%
Inhibrx Biosciences	N/A	-85.12%	-58.90%

Does the media favor VRCA or INBX?

In the previous week, Inhibrx Biosciences had 1 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 3 mentions for Inhibrx Biosciences and 2 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.94 beat Inhibrx Biosciences' score of 0.63 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inhibrx Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals have more ownership in VRCA or INBX?

42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 54.0% of Verrica Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has more volatility and risk, VRCA or INBX?

Verrica Pharmaceuticals has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of -0.04, meaning that its share price is 104% less volatile than the S&P 500.

Do analysts prefer VRCA or INBX?

Verrica Pharmaceuticals presently has a consensus target price of $8.00, suggesting a potential upside of 1,231.11%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Verrica Pharmaceuticals is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20
Inhibrx Biosciences	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Verrica Pharmaceuticals beats Inhibrx Biosciences on 8 of the 15 factors compared between the two stocks.